A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of HRS9531 Injection in Obese Subjects With Polycystic Ovary Syndrome
PHASE2Not yet recruitingINTERVENTIONAL
Enrollment
144
Participants
Timeline
Start Date
September 30, 2024
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
Conditions
Obese Subjects With Polycystic Ovary Syndrome (PCOS)
Interventions
DRUG
HRS9531
HRS9531
DRUG
HRS9531placebo
HRS9531placebo
All Listed Sponsors
lead
Fujian Shengdi Pharmaceutical Co., Ltd.
INDUSTRY
NCT06595797 - A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of HRS9531 Injection in Obese Subjects With Polycystic Ovary Syndrome | Biotech Hunter | Biotech Hunter